Dementia and Alzheimer Disease

Neurology News Network. for the week ending March 15, 2025. [WATCH TIME: 3 minutes]

While effective in reducing amyloid plaques, donanemab carries a notable risk of amyloid-related imaging abnormalities (ARIA), underscoring the need for careful patient monitoring and risk management strategies.

Participants who received the new batch of capsules during the extension phase experienced a lower incidence of falls compared with those taking the old capsules or placebo.

Explore the key 2024 neurology guideline updates shaping clinical care across stroke, epilepsy, movement disorders, and more in this essential feature.

Catch up on any of the neurology news headlines you may have missed over the course of February 2025, compiled all into one place by the NeurologyLive® team.

Lecanemab, a monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid-ß, remains under review, with a decision expected in the coming months.

BXCL501, an orally dissolving dexmedetomidine film, showed positive results in reducing agitation symptoms in patients with Alzheimer disease during the phase 3 TRANQUILITY trial.

Overall, treatment with the anti-tau monoclonal antibody resulted in no serious or severe adverse events, with additional results expected to be presented at an upcoming scientific conference.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on dementia.

Here's some of what is coming soon to NeurologyLive® this week.

A pair of lead neurologists at Baptist Health South Florida provided commentary on some of the promising developments expected to emerge in neurology over the coming months.

Total healthcare costs were 14% higher for patients with potentially inappropriate medication use in the Alzheimer-insomnia cohort, with significant contributions from inpatient care, ambulatory care, and pharmacy costs.

Here's some of what is coming soon to NeurologyLive® this week.

Also known as SNK01, the novel NK cell manufacturing technology enables large-scale ex vivo production and expansion of NK cells.

Monthly cycles of low-dose IL-2, or COYA 301, resulted in statistically significant decreases in proinflammatory biomarkers and increases in anti-inflammatory cytokine IL-4 vs placebo.

Here's some of what is coming soon to NeurologyLive® this week.

The group of women neurologists provided commentary on the critical areas of women-focused research in neurology, from clinical trial participation to addressing workforce challenges.

Panelists explore the challenges and opportunities for women in neurology, offering practical advice for young professionals navigating the field.

In this episode, women neurologists share their personal experiences navigating challenges in neurology, offering insights into mentorship, work-life balance, and career advancement.

Catch up on any of the neurology news headlines you may have missed over the course of January 2025, compiled all into one place by the NeurologyLive® team.

A group of empowering women leaders in neurology explore the transformative impact of women neurologists on the medical workforce and the strides toward a more inclusive neurology field.

Deborah Benzil, MD, FAAS, vice chair of neurosurgery at Cleveland Clinic's Center for Spine Health, shared her extraordinary journey of resilience, from overcoming repeated rejections to becoming a trailblazer for women in neurosurgery, and reflects on the progress made and the challenges that remain.

A group of empowering women leaders in neurology explore the transformative impact of women neurologists on the medical workforce and the strides toward a more inclusive neurology field.

Here's some of what is coming soon to NeurologyLive® this week.

The chair of psychiatry at Tufts University School of Medicine discussed ongoing research exploring the potential of cannabinoids in treating agitation in Alzheimer disease. [WATCH TIME: 5 minutes]